Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | Non-Final OA | Genentech, Inc. |
| 18560113 | SELECTIVE, PARTIAL, AND ARRESTIN-BIASED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS | Non-Final OA | The Regents of the University of California |
| 18416271 | TREATMENT OF SKIN LESIONS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18446296 | Bi-functional Molecules To Degrade Circulating Proteins | Non-Final OA | YALE UNIVERSITY |
| 17756212 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ISCHEMIA-REPERFUSION INJURY AND/OR LUNG INJURY | Non-Final OA | YALE UNIVERSITY |
| 17113571 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | Final Rejection | HANMI PHARM. CO., LTD. |
| 18289453 | METHODS OF USING NMDA RECEPTOR ANTAGONISTS | Final Rejection | GLD Debt Acquisition 2025-1, Inc. |
| 17925750 | DRUG FOR ENHANCING FIBRINOLYTIC SYSTEM, AND USE THEREFOR | Final Rejection | RENASCIENCE INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy